RELIEF-THERAPEUTICS
9.4.2020 09:15:05 CEST | Business Wire | Press release
RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief ” announces that its drug Aviptadil has now entered FDA clinical trials at Thomas Jefferson University Hospital in Philadelphia for the treatment of Acute Respiratory Distress Syndrome (ARDS) in COVID-19. The multicenter trial will enroll patients who are already on mechanical ventilation in the hopes that Aviptadil can decrease mortality in this condition and help to improve the ability of the patient’s lung to transfer oxygen to the body.
“We are delighted to be one of the few centers initiating the clinical study of Aviptadil in patients with COVID-19 induced Acute Respiratory Distress (ARDS). This study focuses on patients who are at the heart of our nation’s crisis, namely those receiving mechanical ventilation and that are already receiving maximal conventional therapy. If successful, we hope that treatments such as Aviptadil may change the chances of survival of these patients,” said Professor Ross Summer, MD, Section Chief of the Critical Care Division of Thomas Jefferson University Hospital, who is serving as principal investigator for this site.
The trial is being led by Relief’s US partner, NeuroRx, Inc., whose clinical operations are based in Radnor, PA, under FDA Investigational New Drug clearance, as part of the FDA’s Corona Treatment Acceleration Program (CTAP). Details of the study are posted on clinicaltrials.gov NCT04311697 .
Death in COVID-19-infected patients is caused in part by a “cytokine storm” in the lungs, in which the virus triggers inflammatory molecules called “cytokines,” which cause the air sacs (alveolae) of the lungs to fill with water and become impermeable to oxygen, even in the setting of mechanical ventilation. VIP is a naturally synthesized peptide which is 40% concentrated in the lungs and which has been shown to have a potent anti-cytokine activity in numerous animal models of respiratory distress, acute lung injury, and inflammation. It has a 20-year history of safe use in human beings in multiple human trials for sarcoidosis, pulmonary fibrosis, and pulmonary hypertension, and is marketed in Europe as a local injection to treat erectile dysfunction.
Relief Therapeutics holds FDA and EU orphan drug designations for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a US patent1 for Aviptadil and proprietary manufacturing processes for its synthesis.
“In a previous trial of VIP for ARDS in patients with sepsis, 7 of 8 patients on mechanical ventilation showed substantial improvement and 6 ultimately left the hospital alive,” said Prof. Jonathan Javitt, MD, MPH, the CEO of NeuroRx, Inc. “Patients on ventilators for COVID-19 have only a 50% chance of survival. If the early results can be replicated in ARDS caused by COVID-19, this treatment could have a major impact both on COVID-19 survival and on the availability of ventilators for those in desperate need.”
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
About RLF-100
RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was originally developed and is currently marketed in Europe for the treatment of erectile dysfunction. VIP is known to be highly concentrated in the lung and to inhibit a variety of inflammatory cytokines. Aviptadil was awarded Orphan Drug Designation in 2001 by the US FDA for treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Aviptadil was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of Acute Lung Injury and in 2007 for the treatment of Sarcoidosis. Both the US FDA and the EMEA have granted Investigational New Drug licenses for human trials of Aviptadil.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF. For further information, please visit the Relief website at www.relieftherapeutics.com or contact at contact@relieftherapeutics.com
Disclaimer : This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
1 US 8,178,489 Formulation for Aviptadil
View source version on businesswire.com: https://www.businesswire.com/news/home/20200409005265/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arini Announces Final Close of Inaugural Direct Lending Fund, Targeting Over $4 Billion of Deployment21.10.2026 09:00:00 CEST | Press release
Arini, an alternative asset manager with $22 billion in assets under management as of 31 August 2026, today announces the final close of Arini Direct Lending Fund I. The Fund and related vehicles are targeting deployment of over $4 billion, including anticipated leverage, making it among the largest debut European direct lending funds ever raised. Arini has built a sizeable initial portfolio throughout the fundraise, focusing on senior secured loans to borrowers demonstrating recurring and underwritable cash flow profiles and operating in industries with limited risk of disruption. Total deployment for the strategy is now approaching $2 billion across a range of sectors and geographies, alongside founder-led, family-owned and sponsor-backed businesses. This scale of deployment, in conjunction with Arini’s highly selective underwriting standards, demonstrates the depth of the European middle market opportunity set. Unlike in the US, banks in Europe have a dominant market share in corpor
LemFi Launches Its Biggest Product Expansion Yet Alongside a New Global Brand, ‘Ambition has no passport’21.10.2026 09:00:00 CEST | Press release
LemFi launches the biggest product expansion in its history, adding UK savings, credit, and data eSIM in 100+ destinations A rebuilt app brings transfers, savings, credit and connectivity together in one platform for people building financial lives across borders New global brand, “Ambition has no passport”, reflects LemFi’s evolution from remittances into a broader financial platform serving more than two million customers LemFi, the financial platform for people building lives across borders, today announced the launch of its new global brand platform, “Ambition has no passport”, alongside a completely rebuilt app, launching the largest product expansion in its history. More than two million customers use LemFi to move money to more than 30 countries, with over $2 billion in monthly transaction volume, and the company plans to add more countries next year. The expanded platform now includes savings and credit in the UK, eSIMs in more than 100 destinations, alongside LemFi’s existing
Skechers Wins Major Victory Against Kizik in Patent Infringement Suit21.10.2026 09:00:00 CEST | Press release
Munich Court States that Kizik’s Patent Infringement Case Against Skechers is “Largely Unfounded” Skechers U.S.A., Inc. (“Skechers”), the third largest footwear company in the world and leader in hands-free footwear technology, announced today that it won a major legal and commercial victory in a patent infringement lawsuit filed by Fast IP, LLC (“Kizik”) against Skechers before the Unified Patent Court (“UPC”) in Munich. Skechers, the market leader in hands-free footwear, sells thousands of styles of hands-free shoes worldwide under its Slip-ins and Swift Fit trademarks. In 2025, Kizik sued Skechers at the UPC for alleged patent infringement involving four of its thousands of hands-free styles. Skechers won on three of the four styles, with the fourth being a minor and commercially insignificant style for Skechers. In its ruling, the Munich Court stated that Kizik’s infringement claims are “largely unfounded.” Skechers’ leading hands-free footwear position globally is the result of it
AI and Multichannel Communication Come to Italian Municipalities21.10.2026 09:00:00 CEST | Press release
ANCIcomunicare and Audiencerate join forces on a new platform for local authorities, built on Microsoft AI and Cloud, distributed by Postel, a Poste Italiane Group company, and available through MEPA ANCIcomunicare and Audiencerate are partnering to provide Italian municipalities and local authorities with a new platform dedicated to data management and multichannel communication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019549522/en/ ANCIcomunicare and Audiencerate launch a partnership to bring Italian municipalities a platform that simplifies data management and digital communication with citizens across all channels. The solution enables municipalities to manage, through a single digital system, communication campaigns aimed at citizens and businesses across multiple channels, including WhatsApp, SMS and e-mail. The platform also integrates Artificial Intelligence and Microsoft Copilot capabilities, designed to s
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 08:00:00 CEST | Press release
Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, software and biology, in the laboratories of an international pharmaceutical group. Servier will use Okomera’s technology to evaluate new therapeutic approaches in oncology and immuno-oncology. Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom